Cegedim SA (LON:0DYQ)
12.15
+0.15 (1.25%)
At close: Nov 12, 2025
Cegedim Revenue
Cegedim had revenue of 322.50M EUR in the half year ending June 30, 2025, with 7.14% growth. This brings the company's revenue in the last twelve months to 658.00M, up 3.79% year-over-year. In the year 2024, Cegedim had annual revenue of 654.50M with 6.25% growth.
Revenue (ttm)
658.00M EUR
Revenue Growth
+3.79%
P/S Ratio
0.26
Revenue / Employee
98.81K EUR
Employees
6,659
Market Cap
147.29M GBP
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 654.50M | 38.50M | 6.25% |
| Dec 31, 2023 | 616.00M | 60.79M | 10.95% |
| Dec 31, 2022 | 555.21M | 30.50M | 5.81% |
| Dec 31, 2021 | 524.71M | 27.77M | 5.59% |
| Dec 31, 2020 | 496.94M | -6.81M | -1.35% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.24B |
| GSK plc | 32.17B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| ConvaTec Group | 1.72B |
| Spire Healthcare Group | 1.55B |
| Genus | 672.80M |
Cegedim News
- 7 weeks ago - Cegedim's profitability improving as expected in H1 2025 - Benzinga